pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2020-30-6-822-830pulmo-2218Research ArticleОБЗОРЫREVIEWБолезнь-модифицирующая терапия бронхиальной астмы: место омализумабаDisease-modifying treatment of asthma: role of omalizumabНовикГ. А.NovikG. A.

Новик Геннадий Айзикович - доктор медицинских наук, профессор, заведующий кафедрой детских болезней имени профессора И.М.Воронцова факультета послевузовского и дополнительного профессионального образования.

Gennadiy A. Novik  - Doctor of Medicine, Professor, Head of I.M.Vorontsov Pediatric diseases Department, Faculty of Postgraduate and Additional Professional Education.

Ul. Litovskaya 2, St. Petersburg, 194100

ga_novik@mail.ruhttps://orcid.org/0000-0002-5999-2150АвдеевС. Н.AvdeevS. N.

Авдеев Сергей Николаевич - доктор медицинских наук, профессор, член-корр. Россий -ской академии наук, заведующий кафедрой пульмонологии.

119991, Москва, ул. Трубецкая, 8, стр. 2; тел.: (495) 708-35-76

Sergey N. Avdeev - Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology.

serg_avdeev@list.ruСоловкинаЮ. В.SolovkinaYu. V.

Соловки на Юлия Владимировна - кандидат медицинских наук, старший медицинский советник.

Yuliya V. Solovkina - Candidate of Medicine, Senior Medical Adviser, “Novartis Pharma” Limited Liability Company.

yuliya.solovkina@novartis.comФедеральное государственное бюджетное образовательное учреждение высшего образования Санкт-Петербургский государственный педиатрический медицинский университет Министерства здравоохранения Российской ФедерацииРоссияSaint-Petersburg State Pediatric Medical University, Healthcare Ministry of RussiaRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М.Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of RussiaRussian FederationОбщество с ограниченной ответственностью Новартис ФармаРоссияNovartis Pharma Limited Liability CompanyRussian Federation202023122020306822830Copyright © Новик Г.А., Авдеев С.Н., Соловкина Ю.В., 20202020Новик Г.А., Авдеев С.Н., Соловкина Ю.В.Novik G.A., Avdeev S.N., Solovkina Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2218

В последние годы в терапии хронических заболеваний наблюдается смена парадигмы лечения со смещением фокуса с симптом-ориентированного подхода на болезнь-модифицирующий. Бронхиальная астма (БА), которая относится к группе хронических заболеваний, не стала исключением. В настоящее время общепринятый подход к дихотомической классификации терапии БА на препараты для профилактики обострений и облегчения симптомов не позволяют отразить их болезнь-модифицирующий потенциал. Понятие «болезнь-модифицирующая терапия БА» может рассматриваться не только с позиции влияния на ремоделирование дыхательных путей (ДП), но и как возможность модифицировать естественное течение БА. Среди биологической терапии наиболее изучено болезнь-модифици-рующее действие омализумаба. Некоторые исследования применения меполизумаба и бенрализумаба направлены на оценку их влияния на ремоделирование ДП. Дальнейшее изучение вопроса болезнь-модифицирующей терапии поможет получить более полное видение ее потенциала в ведении пациентов с БА.

In the past years, we have seen a paradigm shift from symptomatic to disease-modifying approach to the treatment of chronic diseases. The treatment of asthma, which is a chronic disease, is no exception to this shift. Although the available therapies for asthma have been traditionally identified as either “controllers” or “relievers”, this dichotomous classification does not address the therapeutic potential to modify the underlying disease. The disease-modifying therapy for asthma can be defined either as airway remodeling or as modifying the disease's natural course. Among the biological therapies, the disease-modifying effect of omalizumab was studied most comprehensively. Some studies of other biological therapies for severe asthma (mepolizumab, benralizumab) also addressed the airway remodeling effect. A further study of the disease-modifying therapy should help gain a deeper understanding of its potential in managing asthma.

бронхиальная астмаболезнь-модифицирующая терапияремоделированиеомализумабasthmadisease-modifying treatmentairway remodelingomalizumabПубликация подготовлена при информационной поддержке ООО «Новартис Фарма».The publication was created with the informational support of Novartis Pharma Limited Liability CompanyReferencesGlobal Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2020. Available at: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report2006 04-l-wms.pdf [Accessed: April 15, 2020].Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2020. Available at: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf [Accessed: April 15, 2020].Dalgas U., Langeskov-Christensen M., Stenager E. et al. Exercise as medicine in multiple sclerosis-time for a paradigm shift: preventive, symptomatic, and disease-modifying aspects and perspectives. Curr. Neurol. Neurosci. Rep. 2019; 19 (11): 88. DOI: 10.1007/s11910-019-1002-3.Dalgas U., Langeskov-Christensen M., Stenager E. et al. Exercise as medicine in multiple sclerosis-time for a paradigm shift: preventive, symptomatic, and disease-modifying aspects and perspectives. Curr. Neurol. Neurosci. Rep. 2019; 19 (11): 88. DOI: 10.1007/s11910-019-1002-3.Saglani S., Lloyd C.M. Novel concepts in airway inflammation and remodelling in asthma. Eur. Respir. J. 2015; 46 (6): 1796-1804. DOI: 10.1183/13993003.01196-2014.Saglani S., Lloyd C.M. Novel concepts in airway inflammation and remodelling in asthma. Eur. Respir. J. 2015; 46 (6): 1796-1804. DOI: 10.1183/13993003.01196-2014.Levy B.D., Noel P.J., Freemer M.M. et al. Future research directions in asthma. An NHLBI Working Group report. Am. J. Respir. Crit. Care Med. 2015; 192 (11): 1366-1372. DOI: 10.1164/rccm.200311-1539WS.Levy B.D., Noel P.J., Freemer M.M. et al. Future research directions in asthma. An NHLBI Working Group report. Am. J. Respir. Crit. Care Med. 2015; 192 (11): 1366-1372. DOI: 10.1164/rccm.200311-1539WS.NHLBI. Guidelines for the Diagnosis and Management of Asthma (EPR-3). Available at: https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma [Accessed: April 15, 2020].NHLBI. Guidelines for the Diagnosis and Management of Asthma (EPR-3). Available at: https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma [Accessed: April 15, 2020].Lloyd C.M., Robinson D.S. Allergen-induced airway remodelling. Eur. Respir. J. 2007; 29 (5):1020-1032. DOI: 10.1183/09031936.00150305.Lloyd C.M., Robinson D.S. Allergen-induced airway remodelling. Eur. Respir. J. 2007; 29 (5):1020-1032. DOI: 10.1183/09031936.00150305.Bergeron C., Tulic M.K., Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Can. Respir. J. 2010; 17(4): e85-93. DOI: 10.1155/2010/318029.Bergeron C., Tulic M.K., Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Can. Respir. J. 2010; 17(4): e85-93. DOI: 10.1155/2010/318029.Вишнева Е.А., Намазова-Баранова Л.С., Новик Г.А. идр. Актуальная тактика ведения детей с бронхиальной астмой. Педиатрическая фармакология. 2017; 14 (6): 443-458.Vishneva E.A., Namazova-Baranova L.S., Novik G.A. et al. [Actual surveillance of children with bronchial asthma]. Pediatricheskaya farmakologiya. 2017; 14 (6): 443-458 (in Russian).Boulet L.P., Laviolette M., Turcotte H. et al. Bronchial subepithelial fibrosis correlates with airway responsiveness to methacholine. Chest. 1997; 112 (1): 45-52. DOI: 10.1378/chest.112.1.45.Boulet L.P., Laviolette M., Turcotte H. et al. Bronchial subepithelial fibrosis correlates with airway responsiveness to methacholine. Chest. 1997; 112 (1): 45-52. DOI: 10.1378/chest.112.1.45.Wang H., Yao H., Yi B. et al. MicroRNA-638 inhibits human airway smooth muscle cell proliferation and migration through targeting cyclin D1 and NOR1. J. Cell Physiol. 2018; 234 (1): 369-381. DOI: 10.1002/jcp.26930.Wang H., Yao H., Yi B. et al. MicroRNA-638 inhibits human airway smooth muscle cell proliferation and migration through targeting cyclin D1 and NOR1. J. Cell Physiol. 2018; 234 (1): 369-381. DOI: 10.1002/jcp.26930.Benayoun L., Druilhe A., Dombret M.C. et al. Airway structural alterations selectively associated with severe asthma. Am. J. Respir. Crit. Care Med. 2003; 167 (10): 13601368. DOI: 10.1164/rccm.200209-1030OC.Benayoun L., Druilhe A., Dombret M.C. et al. Airway structural alterations selectively associated with severe asthma. Am. J. Respir. Crit. Care Med. 2003; 167 (10): 13601368. DOI: 10.1164/rccm.200209-1030OC.Aikawa T., Shimura S., Sasaki H. et al. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest. 1992; 101: 916-921.Aikawa T., Shimura S., Sasaki H. et al. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest .1992; 101: 916-921.Palgan K., Bartuzi Z. Angiogenesis in bronchial asthma. Int. J. Immunopathol. Pharmacol. 2015; 28 (3): 415-420. DOI: 10.1177/0394632015580907.Palgan K., Bartuzi Z. Angiogenesis in bronchial asthma. Int. J. Immunopathol. Pharmacol. 2015; 28 (3): 415-420. DOI: 10.1177/0394632015580907.Haraguchi M., Shimura S., Shirato K. Morphometric analysis of bronchial cartilage in chronic obstructive pulmonary disease and bronchial asthma. Am. J. Respir. Crit. Care Med. 1999; 159: 1005-1013. DOI: 10.1164/ajrccm.159.3.9712144.Haraguchi M., Shimura S., Shirato K. Morphometric analysis of bronchial cartilage in chronic obstructive pulmonary disease and bronchial asthma. Am. J. Respir. Crit. Care Med. 1999; 159: 1005-1013. DOI: 10.1164/ajrccm.159.3.9712144.Авдеев С.Н. Болезни органов дыхания. М.: Ремедиум; 2020.Avdeev S.N. [Respiratory diseases]. Moscow: Remedium; 2020 (in Russian).Mathur S.K. Allergy and asthma in the elderly. Semin. Respir. Crit. Care Med. 2010; 31 (5): 587-595. DOI: 10.1055/s-0030-1265899.Mathur S.K. Allergy and asthma in the elderly. Semin. Respir. Crit. Care Med. 2010; 31 (5): 587-595. DOI: 10.1055/s-0030-1265899.James A.L., Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur. Respir. J. 2007; 30 (1): 134-155. DOI: 10.1183/09031936.00146905.James A.L., Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur. Respir. J. 2007; 30 (1): 134-155. DOI: 10.1183/09031936.00146905.Rasmussen F., Taylor D.R., Flannery E.M. et al. Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood. Am. J. Respir. Crit. Care Med. 2002; 165 (11): 1480-1488. DOI: 10.1164/rccm.2108009.Rasmussen F., Taylor D.R., Flannery E.M. et al. Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood. Am. J. Respir. Crit. Care Med. 2002; 165 (11): 1480-1488. DOI: 10.1164/rccm.2108009.Dompeling E., van Schayck C.P., van Grunsven P.M. et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann. Intern. Med. 1993; 118 (10): 770-778. DOI: 10.7326/0003-4819-118-10-199305150-00003.Dompeling E., van Schayck C.P., van Grunsven P.M. et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann. Intern. Med. 1993; 118 (10): 770-778. DOI: 10.7326/0003-4819-118-10-199305150-00003.Payne D.N.R., Rogers A.V., Adelroth E. et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am. J. Respir. Crit. Care Med. 2003; 167 (1): 78-82. DOI: 10.1164/rccm.200205-414OC.Payne D.N.R., Rogers A.V., Adelroth E. et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am. J. Respir. Crit. Care Med. 2003; 167 (1): 78-82. DOI: 10.1164/rccm.200205-414OC.Bai T.R., Cooper J., Koelmeyer T. et al. The effect of age and duration of disease on airway structure in fatal asthma. Am. J. Respir. Crit. Care Med. 2000; 162 (2, Pt 1): 663-669. DOI: 10.1164/ajrccm.162.2.9907151.Bai T.R., Cooper J., Koelmeyer T. et al. The effect of age and duration of disease on airway structure in fatal asthma. Am. J. Respir. Crit. Care Med. 2000; 162 (2, Pt 1): 663-669. DOI: 10.1164/ajrccm.162.2.9907151.Bossley C.J., Fleming L., Gupta A. et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J. Allergy Clin. Immunol. 2012; 129 (4): 974-982.e13. DOI: 10.1016/j.jaci.2012.01.059.Bossley C.J., Fleming L., Gupta A. et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J. Allergy Clin. Immunol. 2012; 129 (4): 974-982.e13. DOI: 10.1016/j.jaci.2012.01.059.Castro-Rodriguez J.A., Saglani S., Rodriguez-Martinez C.E. et al. The relationship between inflammation and remodeling in childhood asthma: a systematic review. Pediatr. Pulmonol. 2018; 53 (6): 824-835. DOI: 10.1002/ppul._23968.Castro-Rodriguez J.A., Saglani S., Rodriguez-Martinez C.E. et al. The relationship between inflammation and remodeling in childhood asthma: a systematic review. Pediatr. Pulmonol. 2018; 53 (6): 824-835. DOI: 10.1002/ppul.23968.Russell R.J., Chachi L., FitzGerald J.M. et al. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respir. Med. 2018; 6 (7): 499-510. DOI: 10.1016/S2213-2600(18)30201-7.Russell R.J., Chachi L., FitzGerald J.M. et al. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respir. Med. 2018; 6 (7): 499-510. DOI: 10.1016/S2213-2600(18)30201-7.Yang S.J., Allahverdian S., Saunders A.D.R. et al. IL-13 signaling through IL-13 receptor a2 mediates airway epithelial wound repair. FASEB. J. 2019; 33 (3): 3746-3757. DOI: 10.1096/fj.201801285R.Yang S.J., Allahverdian S., Saunders A.D.R. et al. IL-13 signaling through IL-13 receptor a2 mediates airway epithelial wound repair. FASEB. J. 2019; 33 (3): 3746-3757. DOI: 10.1096/fj.201801285R.Fang L., Sun Q., Roth M. Immunologic and non-immunologic mechanisms leading to airway remodeling in asthma. Int. J. Mol. Sci. 2020; 21 (3): 757. DOI: 10.3390/ijms21030757.Fang L., Sun Q., Roth M. Immunologic and non-immunologic mechanisms leading to airway remodeling in asthma. Int. J. Mol. Sci. 2020; 21 (3): 757. DOI: 10.3390/ijms21030757.Pan S., Conaway S.Jr, Deshpande D.A. Mitochondrial regulation of airway smooth muscle functions in health and pulmonary diseases. Arch. Biochem. Biophys. 2019; 663: 109-119. DOI: 10.1016/j.abb.2019.01.002.Pan S., Conaway S.Jr, Deshpande D.A. Mitochondrial regulation of airway smooth muscle functions in health and pulmonary diseases. Arch. Biochem. Biophys. 2019; 663: 109-119. DOI: 10.1016/j.abb.2019.01.002.Roth M., Zhao F., Zhong J. et al. Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab. PLoS One. 2015; 10 (9): e0136549. DOI: 10.1371/journal.pone.0136549.Roth M., Zhao F., Zhong J. et al. Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab. PLoS One. 2015; 10 (9): e0136549. DOI: 10.1371/journal.pone.0136549.Roth M., Tamm M. The effects of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells. Ann. Allergy Asthma Immunol. 2010; 104 (2): 152-160. DOI: 10.1016/j.anai.2009.11.022.Roth M., Tamm M. The effects of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells. Ann. Allergy Asthma Immunol. 2010; 104 (2): 152-160. DOI: 10.1016/j.anai.2009.11.022.Balhara J., Shan L., Zhang J. et al. Pentraxin 3 deletion aggravates allergic inflammation through a TH17-dominant phenotype and enhanced CD4 T-cell survival. J. Allergy Clin. Immunol. 2017; 139 (3): 950-963.e9. DOI: 10.1016/j.jaci.2016.04.063.Balhara J., Shan L., Zhang J. et al. Pentraxin 3 deletion aggravates allergic inflammation through a TH17-dominant phenotype and enhanced CD4 T-cell survival. J. Allergy Clin. Immunol. 2017; 139 (3): 950-963.e9. DOI: 10.1016/j.jaci.2016.04.063.Fang L., Wang X., Sun Q. et al. IgE downregulates PTEN through microRNA-21-5p and stimulates airway smooth muscle cell remodeling. Int. J. Mol. Sci. 2019; 20 (4): 875. DOI: 10.3390/ijms20040875.Fang L., Wang X., Sun Q. et al. IgE downregulates PTEN through microRNA-21-5p and stimulates airway smooth muscle cell remodeling. Int. J. Mol. Sci. 2019; 20 (4): 875. DOI: 10.3390/ijms20040875.Kardas G., Kuna P., Panek M. Biological therapies of severe asthma and their possible effects on airway remodeling. Front. Immunol. 2020; 11: 1134. DOI: 10.3389/fimmu.2020.01134.Kardas G., Kuna P., Panek M. Biological therapies of severe asthma and their possible effects on airway remodeling. Front. Immunol. 2020; 11: 1134. DOI: 10.3389/fimmu.2020.01134.Backman K.S., Greenberger P.A., Patterson R. Airways obstruction in patients with long-term asthma consistent with ‘‘irreversible asthma’’. Chest. 1997; 112 (5): 1234-1240. DOI: 10.1378/chest.112.5.1234.Backman K.S., Greenberger P.A., Patterson R. Airways obstruction in patients with long-term asthma consistent with ‘‘irreversible asthma’’. Chest. 1997; 112 (5): 1234-1240. DOI: 10.1378/chest.112.5.1234.Авдеев С.Н., Аксельрод А.С., Александров М.В. и др. Функциональная диагностика: национальное руководство. М.: ГЭОТАР-Медиа; 2019.Avdeev S.N., Aksel'rod A.S., Aleksandrov M.V. et al. [Functional diagnostics: national guidelines]. Moscow: GEOTAR-Media; 2019 (in Russian).Huang Y.C., Leyko B., Frieri M. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann. Allergy Asthma Immunol. 2005; 95 (5): 443-451. DOI: 10.1016/S1081-1206(10)61170-2.Huang Y.C., Leyko B., Frieri M. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann. Allergy Asthma Immunol. 2005; 95 (5): 443-451. DOI: 10.1016/S1081-1206(10)61170-2.Riccio A.M., Dal Negro R.W., Micheletto C. et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int. J. Immunopathol. Pharmacol. 2012; 25 (2): 475-484. DOI: 10.1177/039463201202500217.Riccio A.M., Dal Negro R.W., Micheletto C. et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int. J. Immunopathol. Pharmacol. 2012; 25 (2): 475-484. DOI: 10.1177/039463201202500217.Riccio A.M., Mauri P., De Ferrari L. et al. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. Clin. Transl. Allergy. 2017; 7: 6. DOI: 10.1186/s13601-017-0143-1.Riccio A.M., Mauri P., De Ferrari L. et al. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. Clin. Transl. Allergy. 2017; 7: 6. DOI: 10.1186/s13601-017-0143-1.ZastrzezyAska W., Przybyszowski M., Bazan-Socha S. et al. Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics. J. Asthma. 2020; 57 (5): 468-477. DOI: 10.1080/02770903.2019.1585872.ZastrzezyAska W., Przybyszowski M., Bazan-Socha S. et al. Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics. J. Asthma. 2020; 57 (5): 468-477. DOI: 10.1080/02770903.2019.1585872.Mauri P., Riccio A.M., Rossi R. et al. Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol. Lett. 2014; 162 (1): 2-10. DOI: 10.1016/j.imlet.2014.08.010.Mauri P., Riccio A.M., Rossi R. et al. Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol. Lett. 2014; 162 (1): 2-10. DOI: 10.1016/j.imlet.2014.08.010.Hoshino M., Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012; 83 (6): 520-528. DOI: 10.1159/000334701.Hoshino M., Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012; 83 (6): 520-528. DOI: 10.1159/000334701.Tajiri T., Niimi A., Matsumoto H. et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a timeseries observational study. Ann. Allergy Asthma Immunol. 2014; 113 (4): 470-475.e2. DOI: 10.1016/j.anai.2014.06.004.Tajiri T., Niimi A., Matsumoto H. et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a timeseries observational study. Ann. Allergy Asthma Immunol. 2014; 113 (4): 470-475.e2. DOI: 10.1016/j.anai.2014.06.004.Flood-Page P., Menzies-Gow A., Phipps S. et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 2003; 112 (7): 1029-1036. DOI: 10.1172/JCI17974.Flood-Page P., Menzies-Gow A., Phipps S. et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 2003; 112 (7): 1029-1036. DOI: 10.1172/JCI17974.Haldar P., Brightling C.E., Hargadon B. et al. Mepoli-zumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009; 360 (10): 973-984. DOI: 10.1056/NEJMoa0808991.Haldar P., Brightling C.E., Hargadon B. et al. Mepoli-zumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009; 360 (10): 973-984. DOI: 10.1056/NEJMoa0808991.Saunders R., Kaul H., Berair R. et al. DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment. Sci. Transl. Med. 2019; 11 (479): eaao6451. DOI: 10.1126/scitranslmed.aao6451.Saunders R., Kaul H., Berair R. et al. DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment. Sci. Transl. Med. 2019; 11 (479): eaao6451. DOI: 10.1126/scitranslmed.aao6451.Chachi L., Diver S., Kaul H. et al. Computational modelling prediction and clinical validation of impact of benral-izumab on airway smooth muscle mass in asthma. Eur. Respir. J. 2019; 54 (5): 1900930. DOI: 10.1183/13993003.00930-2019.Chachi L., Diver S., Kaul H. et al. Computational modelling prediction and clinical validation of impact of benral-izumab on airway smooth muscle mass in asthma. Eur. Respir. J. 2019; 54 (5): 1900930. DOI: 10.1183/13993003.00930-2019.Salter H.H. On asthma: its pathology and treatment. London: Churchill; 1860.Salter H.H. On asthma: its pathology and treatment. London: Churchill; 1860.O'Byrne P., Fabbri L.M., Pavord I.D. et al. Asthma progression and mortality: the role of inhaled corticosteroids. Eur. Respir. J. 2019; 54 (1): 1900491. DOI: 10.1183/13993003.00491-2019.O'Byrne P., Fabbri L.M., Pavord I.D. et al. Asthma progression and mortality: the role of inhaled corticosteroids. Eur. Respir. J. 2019; 54 (1): 1900491. DOI: 10.1183/13993003.00491-2019.Новик Г.А., Вишнева Е.А., Намазова-Баранова Л.С. Приверженность: роль в достижении контроля над бронхиальной астмой у детей. Педиатрическая фармакология. 2015; 12 (2): 190-196.Novik G.A., Vishneva E.A., Namazova-Baranova L.S. [Adherence: its role in achieving control over bronchial asthma in children]. Pediatricheskaya farmakologiya. 2015; 12 (2): 190-196 (in Russian).Baena-Cagnani C.E., Teijeiro A., Canonica G.W. Fouryear follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Curr. Opin. Allergy Clin. Immunol. 2015; 15 (3): 267-271. DOI: 10.1097/ACI.0000000000000161.Baena-Cagnani C.E., Teijeiro A., Canonica G.W. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Curr. Opin. Allergy Clin. Immunol. 2015; 15 (3): 267-271. DOI: 10.1097/ACI.0000000000000161.Vennera M.D.C., Sabadell C., Picado C. Duration of the efficacy of omalizumab after treatment discontinuation in “real life” severe asthma. Thorax. 2018; 73 (8): 782-784. DOI: 10.1136/thoraxjnl-2017-210017.Vennera M.D.C., Sabadell C., Picado C. Duration of the efficacy of omalizumab after treatment discontinuation in “real life” severe asthma. Thorax. 2018; 73 (8): 782-784. DOI: 10.1136/thoraxjnl-2017-210017.

The authors declare that there are no conflicts of interest present.